Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.40 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125726 | 1.00 | LMNA (0.45) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL5748460 | 0.90 | LMNA (0.48) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL18926552 | 0.86 | PSMD10 (0.45) | CYP3A4ALDH1A1CYP24A1PSMD10VDR | |
| SCHEMBL6098372 | 0.84 | ALDH1A1 (0.48) | LMNACYP3A4CYP2D6MAPK1THPO | |
| SCHEMBL18926562 | 0.81 | CNR2 (0.44) | CYP3A4ALDH1A1CYP24A1PSMD10VDR | |
| SCHEMBL890725 | 0.81 | ALDH1A1 (0.50) | CYP3A4CYP2D6ALDH1A1CYP24A1PSMD10 | |
| SCHEMBL2310681 | 0.80 | FKBP1A (0.51) | LMNACYP3A4ALDH1A1CYP24A1KMT2A | |
| SCHEMBL24456702 | 0.80 | ALDH1A1 (0.48) | LMNACYP3A4CYP2D6MAPK1THPO | |
| Water SCHEMBL17044635 | 0.80 | CA12 (0.41) | LMNAALDH1A1CYP24A1PSMD10VDR | |
| SCHEMBL7655861 | 0.80 | ALDH1A1 (0.46) | LMNAMAPK1ALDH1A1CYP24A1PSMD10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-115298175-B | Macrocyclic PAD4 inhibitors useful as immunosuppressants | 百时美施贵宝公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4100405-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | Bristol-Myers Squibb Company (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115298175-A | Macrocyclic PAD4 inhibitors useful as immunosuppressants | 百时美施贵宝公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021158840-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | PADI4, PADI1, PADI2 | LMNA 4757/4885CYP3A4 85/4885CYP2D6 429/4885 |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | LMNA 4757/4885CYP3A4 85/4885CYP2D6 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.